2-Star Stocks Poised to Plunge: Neurocrine Biosciences?

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Neurocrine Biosciences (Nasdaq: NBIX  ) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Neurocrine's business and see what CAPS investors are saying about the stock right now.

Neurocrine facts

Headquarters (Founded) San Diego, Calif. (1992)
Market Cap $522.6 million
Industry Biotechnology
Trailing-12-Month Revenue $74.6 million
Management CEO Kevin Gorman
CFO Timothy Coughlin
Trailing-12-Month Return on Equity 36.8%
Cash/Debt $177.5 million / $0
Competitors Abbott Labs
Eli Lilly
Pfizer

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 14% of the 360 members who have rated Neurocrine believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped Neurocrine as "dead money" in the short run:

Neurocrine has been turning in solid pipeline progress for several years now but they haven't had much success holding gains in the share price. Now that the phase III trial of [E]lagolix is in progress I expect at least a year before all 875 patients are enrolled and possibly another year before topline data is released. I'm not expecting any other catalysts in the near future and if previous patterns hold the share price will drift back below [$7] before the runup into phase III data.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2013446, ~/Articles/ArticleHandler.aspx, 10/23/2014 4:15:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement